Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2013 | short review

The contribution of antibodies to targeted cancer therapy

verfasst von: Panagiotis Apostolou, Dr. Ioannis Papasotiriou

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The fight against cancer is the focus of many research groups, as it is classified as one of the leading causes of death. The treatment of cancer is mainly composed of surgery, chemotherapy, radiation therapy, immunotherapy, and nowadays through targeted therapy as well. Targeted therapy targets the molecules whose expression correlates to carcinogenesis. It can be performed either with small molecule drugs or with monoclonal antibodies. Based on the capacity of the monoclonal antibodies to recognize a certain epitope of an antigen, and the fact that cancer cells express many antigens compared with normal (noncancer) cells abnormally in their surface, cytotoxicity may be induced directly in these cells. The cytotoxicity can be caused either via antibody-dependent cellular interaction or via the complement system. The possibility to create monoclonal antibodies against any antigen led to production of new medicines, many of which are already in clinical use. The ability to conjugate several molecules to antibodies also made the delivery of drugs/substances directly to cancer cells possible, thereby reducing the side effects of cancer treatment. This review presents the implementation of antibodies to targeted therapy, emphasizing the antibody-dependent cytotoxicity, as well as the monoclonal antibodies that are used in cancer treatment.
Vorheriger Artikel Transfusion-associated graft-versus-host disease: an update
Nächster Artikel Targeted delivery of anticancer agents using antibodies as vectors
Literatur
1.
Joensuu H. Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Ann Med. 2000 Feb;32(1):31–3.
2.
Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294–7.
3.
Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2.
4.
Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs. 2005 Jan;14(1):45–55.
5.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Apr;12(4):278–87.
6.
Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–62.
7.
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–6.
8.
Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005 Jan 31;92(2):342–9.
9.
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease,. 5th edn. New York: Garland Science; 2001.
10.
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006 Apr;6(4):295–307.
11.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003 Jun;8(3):237–49.
12.
Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):73–80.
13.
Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2013 Jan 8. doi: 10.1038/tpj.2012.54. (Epub ahead of print)
14.
Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51.
15.
Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013 Sep 15;19(18):4911–6.
16.
Thomas DA, O’Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):949–71, v.
17.
Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393–402.
18.
Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58.
19.
Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol. 2009 Sep;46(14):2794–800.
20.
Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889–95.
21.
Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005:329–34.
22.
Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003 Mar;9(3):269–77.
23.
Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013 Sep 13;341(6151):1192–8.
24.
Zhang B. Ofatumumab. MAbs. 2009 Jul-Aug;1(4):326–31.
25.
Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875–82.
26.
Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328–35.
27.
Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15–25.
28.
Prieto PA, Yang JC, Sherry RM, Hughes MS,Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 1;18(7):2039–47.
29.
Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, Erro L, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011 Jul 15;129(2):374–86.
30.
Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000 Aug;61(8):721–8.
31.
Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009 Nov-Dec;1(6):539–47.
32.
Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010 Mar-Apr;2(2):129–36.
33.
Pescovitz MD. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Expert Rev Clin Immunol. 2005 Sep;1(3):337–44.
34.
Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013 Mar 15;31(12):1553–9.
35.
Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb;33(2):199–211.
36.
Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 2006 Oct;19(10):471–8.
37.
Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Sep;70(3):407–14.
Metadaten
Titel
The contribution of antibodies to targeted cancer therapy
verfasst von
Panagiotis Apostolou
Dr. Ioannis Papasotiriou
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0117-5

Weitere Artikel der Ausgabe 4/2013

Transfusion-associated graft-versus-host disease: an update

  • short review

Targeted delivery of anticancer agents using antibodies as vectors

  • short review

Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

  • short review

Antibody–drug conjugates (ADCs)—new targeted therapies

  • editorial

ASCO annual meeting 2013: head and neck cancer

  • short review

ASCO 2013: new developments in lung cancer

  • short review